Takao Sanaki

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

Yuto Unoh, Shota Uehara, Kenji Nakahara et al. · Journal of Medicinal Chemistry · 2022 · 590 citations · Full text

Medicine, Infectious Diseases, Pharmacology +15

SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells

Michihito Sasaki, Kentaro Uemura, Akihiko Sato et al. · PLoS Pathogens · 2021 · 213 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +17

Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study

Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari et al. · Clinical Infectious Diseases · 2022 · 155 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part

Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari et al. · Antimicrobial Agents and Chemotherapy · 2022 · 136 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19

Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi et al. · JAMA Network Open · 2024 · 114 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15